Navigation Links
DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors
Date:3/16/2009

EWING, N.J., March 16 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company) announced today that it has appointed Gregg Lapointe, CPA, MBA, to its Board of Directors. Mr. Lapointe is currently Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau), a company dedicated to the development and commercialization of medicines for patients with rare diseases. Sigma-Tau is DOR's North American partner for orBec(R) and its largest shareholder.

Mr. Lapointe has served in various roles for Sigma-Tau since 2001, including Chief Operating Officer from November 2003 to April 2008 and Chief Executive Officer since April 2008. Prior to Sigma-Tau, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Prior to that, Mr. Lapointe spent several years in the Canadian medical products industry in both medical products distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. He received his BA in Commerce from Concordia University in Montreal, Canada, a graduate diploma in accountancy from McGill University and his MBA from Duke University. He is also a CPA in the state of Illinois and a Chartered Accountant in Ontario, Canada. Mr. Lapointe also serves on the Board of Directors of the Pharmaceuticals Research and Manufacturers of America (PhRMA) and is a member of the Corporate Council of the National Organization for Rare Diseases (NORD).

"We are very pleased to welcome Gregg Lapointe to our Board of Directors," said Christopher J. Schaber, PhD, President and CEO of DOR. "Mr. Lapointe brings extensive experience in the areas of global strategic planning and implementation, corporate finance, accounting, and acquisitions. With his strong business and healthcare background, he is well positioned to make significant contributions to the continued growth and success of DOR. We are enthu
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
2. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
4. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
7. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
8. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
9. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
10. Eiger BioPharmaceuticals Raises $7.1 Million A Round
11. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... DUBLIN , Feb. 27, 2015 Research and Markets ... the "Global Market Report of Trypsin" report to ... Trypsin (CAS 9002-07-7) aims at providing comprehensive data on Trypsin ... Asia , North America , ... trends, pays close attention to Trypsin This report ...
(Date:2/27/2015)... February 27, 2015 The fully ... (Nexera UC) can sequentially analyze up to 48 ... with high-sensitivity detection of targets by mass spectrometry. ... to fulfill the measurement requirements of a wide ... products, drug delivery and search for disease biomarkers, ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
(Date:2/27/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... with patients and health care advocates in the United ... Day®. Rare Disease Day is dedicated to elevating ... the special challenges faced by patients with rare diseases ... proud to stand alongside patients and caregivers representing the ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6
... Brings Growth Opportunities in Transplant Diagnostics, Genetic Testing ... DIEGO, April 8 Gen-Probe (Nasdaq: ... completed its acquisition of Tepnel Life Sciences, plc, ... company based in the United Kingdom, for 27.1 ...
... and Peru , expansion of ... to reduce drug development timelines for biopharmaceutical companies - PRINCETON, ... ) today announced the recent opening of new clinical development ... of the company,s Buenos Aires, Argentina office. These latest ...
... CHICAGO, April 7 The following release is ... http://www.newscom.com/cgi-bin/prnh/20090325/DC89081LOGO ... on the importance of medical science and discovery ... changes are critical to maintaining America,s leadership in ...
Cached Biology Technology:Gen-Probe Completes Acquisition of Tepnel Life Sciences 2Gen-Probe Completes Acquisition of Tepnel Life Sciences 3Gen-Probe Completes Acquisition of Tepnel Life Sciences 4Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office 2Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office 3Council for American Medical Innovation Brings U.S. Leaders in Medicine, Biotechnology and Discovery Together in Chicago for 'Best and Brightest Forum on Medical Innovation' 2
(Date:2/23/2015)... OXFORD, Conn. , Feb. 23, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62114357 for ... With this patent, NXT-ID introduces a new groundbreaking payment ... and the payment account may only be accessed if ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... Following an intense study of agricultural ecosystems near ... analysis and management of a wide range of ... of McGill University,s Department of Geography, Elena Bennett ... Peterson of the Stockholm Resilience Centre at Stockholm ...
... Gorun, PhD, associate professor of chemistry at New ... was awarded a patent today for a novel ... Perfluoroalkyl Perfluoro-Phthalocyanine Compounds" (US Patent Number 7,670,684) discloses ... new materials are comprised of organic scaffolds with ...
... 2010 In one of the most comprehensive global studies ... from the University of Rhode Island and other institutions has ... driving the success of marine reserves. "We make a ... coral, fish and other aquatic organisms," said Richard Pollnac, URI ...
Cached Biology News:Seeing the hidden services of nature 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2Scientists find community involvement, not only enforcement, drives success of marine reserves 2
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Tissue culture grade....
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... The Nick Translation System is ideal ... DNA. The Nick Translation System: Provides ... labeled nucleotide incorporation Yields >10 8 ... Includes control DNA to monitor the performance ...
Biology Products: